Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 1, 2026

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.

Margaret A Shipp1, Ken N Ross, Pablo Tamayo

  • 1Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA. margaret_shipp@dfci.harvard.edu

Nature Medicine
|January 12, 2002
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EpiATLAS - a reference for human epigenomic research.

bioRxiv : the preprint server for biology·2026
Same author

A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.

Blood advances·2026
Same author

Atorvastatin and left ventricular strain during anthracycline-based chemotherapy.

International journal of cardiology·2026
Same author

Cancer Susceptibility to Stapled Oncolytic Peptides Is Dictated by Membrane Cholesterol and Inflammatory Signaling.

Cancer research·2026
Same author

Feasibility of decentralized real-world monitoring of SARS-CoV-2 booster vaccines and COVID-19 outcomes in myeloma.

Blood advances·2026
Same author

CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.

Blood advances·2026
Same journal

Generalizable AI predicts immunotherapy outcomes across cancers and treatments.

Nature medicine·2026
Same journal

Immune aging biomarkers for clinical trials.

Nature medicine·2026
Same journal

Lassa fever countermeasures gather pace.

Nature medicine·2026
Same journal

Why high scores do not mean application readiness for health AI.

Nature medicine·2026
Same journal

Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trial.

Nature medicine·2026
Same journal

Biological aging might help to explain the rising risk of early-onset cancer.

Nature medicine·2026
See all related articles
This summary is machine-generated.

This study uses machine learning to predict diffuse large B-cell lymphoma (DLBCL) patient outcomes. The new model identifies patients likely to be cured by chemotherapy, improving treatment strategies.

Area of Science:

  • Hematology
  • Oncology
  • Computational Biology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is a common aggressive lymphoma with less than 50% cure rates.
  • Current prognostic models like the International Prognostic Index (IPI) lack molecular insights and therapeutic targets.

Purpose of the Study:

  • To develop a predictive model for DLBCL patient outcomes using gene expression data.
  • To identify molecular targets for improved DLBCL treatment strategies.

Main Methods:

  • Analyzed gene expression of 6,817 genes from DLBCL tumor samples.
  • Applied supervised learning to classify patients into distinct outcome groups.
  • Validated model performance across different International Prognostic Index (IPI) risk categories.

More Related Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Related Experiment Videos

Last Updated: Jul 1, 2026

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Main Results:

  • A supervised learning algorithm predicted patient outcomes with distinct five-year survival rates (70% vs. 12%).
  • The model accurately identified patients likely to be cured or experience refractory disease within IPI risk groups.
  • Identified key genes involved in B-cell-receptor signaling, phosphorylation, and apoptosis pathways linked to DLBCL outcome.

Conclusions:

  • Supervised learning classification effectively predicts DLBCL patient outcomes.
  • This approach can identify potential molecular targets for novel DLBCL therapeutic interventions.